secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001213900-24-053982
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns
-------------------------------------------------------------------------

- Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.
- Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.
- Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.
- Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.
- Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/0001213900-24-053982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024053982/ea0208074-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-053982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer